Compare Adaptive Biotechnologies Corp (ADPT) vs Kaltura Inc (KLTR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Kaltura Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Kaltura Inc trades at $1.25 (market cap $193.23M). The key difference: Adaptive Biotechnologies Corp is far larger — about 17.2× Kaltura Inc's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Kaltura Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | KLTR | |
|---|---|---|
Market Cap | $3.33B | $193.23M |
Sector | Health | Technology |
52-Week High | $22.37 | $2.01 |
52-Week Low | $10.24 | $1.08 |
Enterprise Value | $3.19B | $175.95M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Kaltura (KLTR) trades at $1.29, up 2.38% with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with revenue stabilizing around $180M and narrowing losses, though it remains unprofitable with negative margins. Recent industry recognition and AI product launches highlight strategic positioning in digital experience platforms.
Investment outlook balances operational improvements against persistent profitability challenges. Positive analyst sentiment (44% buy ratings) and strong institutional coverage suggest potential upside if AI initiatives drive growth, but high P/B ratio and negative cash flow pose risks for near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Kaltura Inc
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)
Read more on KLTR →
